Timothy Cloughesy
· ProfessorUniversity of California, Los Angeles · Nuclear Medicine & Theranostics
Active 1992–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Dr. Timothy Cloughesy is a Professor of Neurology and Molecular and Medical Pharmacology at the University of California, Los Angeles. He is a member of the UCLA Brain Research Institute and the Jonsson Comprehensive Cancer Center, as well as the Director of the UCLA Neuro-Oncology Program, the UCLA Brain Tumor Center, and the Henry Singleton Brain Cancer Research Program. Dr. Cloughesy received his B.A. degree with honors from the University of California, Santa Barbara, and his M.D. from Tulane University. He completed his neurology residency and fellowships in clinical neurophysiology at UCLA. He is board certified in neurology and clinical neurophysiology and holds the UCNS Neuro-Oncology Certification. His research encompasses therapeutic, imaging, translational, and basic investigations in brain cancer. He has extensive experience with clinical trials involving small molecule inhibitors, antibodies, antibody drug conjugates, chemotherapies, vaccines, viral gene transfer, and immune checkpoint therapies. Dr. Cloughesy has played leadership roles in first-in-human studies, pharmacokinetics/pharmacodynamics studies, and traditional Phase I through Phase III trials. His focus on clinical trials in brain cancer includes novel clinical trial design, biomarker incorporation, and development of new biomarkers. He provided principal leadership for the accelerated approval and the conversion to full approval of bevacizumab for recurrent glioblastoma. He developed a brain cancer…
Research topics
- Medicine
- Internal medicine
- Computer Science
- Cancer research
- Oncology
- Artificial Intelligence
- Nuclear medicine
- Pathology
- Machine Learning
- Radiology
Selected publications
Neuro-Oncology · 2020 · 1111 citations
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase w…
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
New England Journal of Medicine · 2023 · 683 citations
Senior authorCorrespondingBACKGROUND: Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas. METHODS: In a double-blind, phase 3 trial, we randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib…
Neuro-Oncology · 2022 · 463 citations
BACKGROUND: Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit. The aim of this open-label, phase III CheckMate 498 study was to evaluate the efficacy of nivolumab (NIVO) + RT compared with TMZ + RT in newly diagnosed GBM with unmethylated MGMT promoter. METHODS: Patients were randomized 1:1 to standard RT (60 G…
Federated learning enables big data for rare cancer boundary detection
Nature Communications · 2022 · 326 citations
Although machine learning (ML) has shown promise across disciplines, out-of-sample generalizability is concerning. This is currently addressed by sharing multi-site data, but such centralization is challenging/infeasible to scale due to various limitations. Federated ML (FL) provides an alternative paradigm for accurate and generalizable ML, by only sharing numerical model updates. Here we present the largest FL study to-date, involving data from 71 sites across 6 continents, to generate an auto…
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine · 2023 · 255 citations
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab in recurrent glioblastoma, first in a dose-escalation and then in a dose-expansion phase, in 49 patients. The primary endpoints were overall safety and…
Recent grants
NIH · $35.6M · 2017–2027
NIH · $720k · 2008
NIH · $4.4M · 2017–2022
Frequent coauthors
- 2691 shared
Patrick Y. Wen
- 1533 shared
Lisa M. DeAngelis
Memorial Sloan Kettering Cancer Center
- 1284 shared
Minesh P. Mehta
- 1204 shared
Michael D. Prados
University of California, San Francisco
- 1140 shared
David A. Reardon
Dana-Farber Cancer Institute
- 987 shared
J. Raizer
Columbia University
- 941 shared
John G. Kuhn
University of California, Los Angeles
- 913 shared
Lauren E. Abrey
Roche (Switzerland)
Similar researchers at University of California, Los Angeles
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Timothy Cloughesy
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup